Yubo International Biotech Limited
YBGJ · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.20 | -0.07 | 0.00 |
| FCF Yield | -18.12% | 0.49% | -6.73% | -22.46% |
| EV / EBITDA | -7.91 | -44.20 | -14.53 | -14.89 |
| Quality | ||||
| ROIC | 21.19% | 6.58% | 13.68% | 12.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 72.22% |
| Cash Conversion Ratio | 1.64 | -0.50 | 0.84 | 2.64 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -87.90% | -49.74% | -49.99% |
| Free Cash Flow Growth | -930.45% | 110.86% | 57.30% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | -0.85 | -0.52 | -1.52 |
| Interest Coverage | -17,229.67 | -10,856.48 | -24,594.68 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.15 | 1.20 | 1.20 | -0.00 |
| Cash Conversion Cycle | -1,898.22 | -2,019.23 | -1,911.02 | 15,804,064.00 |